Registered dietitian Cami Jacobsen of Avera Health talks about diet changes that may help people cut down the side effects of GLP-1 medications.
Recap by typeshit. Post by Facebook on Facebook.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A piece on questions about tirzepatide and breast cancer risk. Only the headline is available, so check the source for what the evidence says.
With about 11% of the US on a GLP-1 for weight loss, Mayo Clinic tackles how much loss is enough and what helps keep the weight off.
Its 2025 comparison puts the two biggest GLP-1 drugs at roughly double the combined revenue of the two AI labs, with a chart attached.
Loading…